| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/09/2006 | US20060029608 Immunization against clostridium difficile disease |
| 02/09/2006 | US20060029607 Methods and compositions for modulating tumor growth |
| 02/09/2006 | US20060029606 Insulin-like growth factor (IGF); peptide of given sequence; administered with co-agent such as doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, 5-fluorouracil; anticarcinogen |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029604 Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| 02/09/2006 | US20060029603 Immunoglobulins |
| 02/09/2006 | US20060029602 secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner |
| 02/09/2006 | US20060029601 isolated human monoclonal antibodies or antigen binding portion, that bind to IFNAR-1, capable of blocking the action of type I interferons; use in the treatment of immune mediated disorders, including autoimmune disorders, transplant rejection and Graft Versus Host Disease (GVHD) |
| 02/09/2006 | US20060029600 Treatment of viral encephalitis by agents blocking alpha-VLA-4 integrin function |
| 02/09/2006 | US20060029599 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 02/09/2006 | US20060029598 Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions |
| 02/09/2006 | US20060029597 IgA antibody protein as a cytotoxic drug |
| 02/09/2006 | US20060029596 Administering to the tumor an adenovirus vector, overexpresses an adenovirus death protein; promoting the death of neoplastic cells; telomerase resistance; anticancer biodrugs |
| 02/09/2006 | US20060029595 Methods of using human receptor protein 4-1BB |
| 02/09/2006 | US20060029594 Interleukins (IL-5); for treating conditions associated with excess eosinophil production (such as chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, coeliac disease and/or gastroenteritis) |
| 02/09/2006 | US20060029593 Immunoglobulins having complementarity determining regions, heavy and light chain variable regions from humans that specifically bind to an antigen with affinity, used for in vivo therapy and diagnosis |
| 02/09/2006 | US20060029581 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 02/09/2006 | US20060029547 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 02/09/2006 | US20060029543 Treatment of B-cell lymphoma |
| 02/09/2006 | CA2855056A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2638747A1 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | CA2592044A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 02/09/2006 | CA2576124A1 Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens |
| 02/09/2006 | CA2576093A1 Pharmaceutical compostion containing meltrin antagonist |
| 02/09/2006 | CA2576037A1 Method of producing glycoprotein composition |
| 02/09/2006 | CA2575901A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2575898A1 Vaccine for prevention and treatment of hiv-infection |
| 02/09/2006 | CA2575610A1 Hpv vaccine comprising peptides from host cell proteins |
| 02/09/2006 | CA2575402A1 Humanized anti-cmet antagonists |
| 02/09/2006 | CA2575348A1 Novel anti-igf-ir antibodies and uses thereof |
| 02/09/2006 | CA2574881A1 Antibodies to dkk-1 |
| 02/09/2006 | CA2574176A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | CA2573864A1 Immunoglobulins comprising predominantly a glcnacman5glcnac2 glycoform |
| 02/09/2006 | CA2573842A1 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform |
| 02/09/2006 | CA2573586A1 Il-17 antagonistic antibodies |
| 02/09/2006 | CA2573554A1 Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| 02/09/2006 | CA2573541A1 Immunoglobulins comprising predominantly a man3glcnac2 glycoform |
| 02/09/2006 | CA2573259A1 High affinity anti-tnf-alpha antibodies and method |
| 02/09/2006 | CA2570643A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 02/09/2006 | CA2568886A1 Compositions and methods for treatment of non-hodgkin's lymphoma |
| 02/09/2006 | CA2567795A1 Methods of treating type i diabetes by blocking vegf-mediated activity |
| 02/08/2006 | EP1624068A1 Genetic immunization with cationic lipids |
| 02/08/2006 | EP1624064A2 Nucleic acids and proteins from streptococcus pneumoniae |
| 02/08/2006 | EP1624063A2 Chimeric gene encoding the antigenic determinants of four proteins of L. infantum |
| 02/08/2006 | EP1623990A2 Compositions and methods for the treatment of tumours |
| 02/08/2006 | EP1623989A1 Compositions and methods for the diagnosis of tumours |
| 02/08/2006 | EP1623720A2 Vaccine composition against malaria |
| 02/08/2006 | EP1623719A1 Alzheimer's disease treatment method |
| 02/08/2006 | EP1623221A2 Modulators of the p2y10 receptor useful in altering t lymphocyte function |
| 02/08/2006 | EP1623015A2 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/08/2006 | EP1623012A2 ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 02/08/2006 | EP1623011A2 IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| 02/08/2006 | EP1623006A2 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| 02/08/2006 | EP1622942A2 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 02/08/2006 | EP1622937A2 Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| 02/08/2006 | EP1622935A2 Spex compositions and methods of use |
| 02/08/2006 | EP1622933A2 H. pylori antigens |
| 02/08/2006 | EP1622648A2 Dna vaccines against tumor growth and methods of use thereof |
| 02/08/2006 | EP1622644A2 Materials and methods for immunizing against fiv infection |
| 02/08/2006 | EP1622643A2 Avian combination-vaccine against e. coli and salmonella |
| 02/08/2006 | EP1622642A1 Avian e. coli vaccine for the protection against colibacillosis |
| 02/08/2006 | EP1622641A2 Vaccinating against infectious diseases using proteosomes |
| 02/08/2006 | EP1622574A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 02/08/2006 | EP1622573A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/08/2006 | EP1622570A2 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| 02/08/2006 | EP1622566A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| 02/08/2006 | EP1622565A2 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 02/08/2006 | EP1622563A2 Improved heat shock protein-based vaccines and immunotherapies |
| 02/08/2006 | EP1352052B1 Method for preparing submicron particle suspensions of pharmaceutical agents |
| 02/08/2006 | EP1333858B1 Vaccines with enhanced immune response and methods for their preparation |
| 02/08/2006 | EP1226176B1 Production of mammary secretion antibodies in farm animals |
| 02/08/2006 | EP1068297B1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency |
| 02/08/2006 | EP1039933B1 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE AND FOR THE PRODUCTION OF $i(IN VITRO) MABS |
| 02/08/2006 | EP1032669B1 Recombinant allergen with reduced enzymatic activity |
| 02/08/2006 | EP1025230B1 ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| 02/08/2006 | EP0969855B1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/08/2006 | EP0812356B1 Prostate-specific membrane antigen and uses thereof |
| 02/08/2006 | EP0694067B1 T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| 02/08/2006 | CN1732183A Multiple variants of meningococcal protein NMB1870 |
| 02/08/2006 | CN1732017A Combinations of growth- and hormone-regulating factors for the treatment of neoplasia |
| 02/08/2006 | CN1732015A Low dose methods for treating disorders in which TNF-alpha activity is detrimental |
| 02/08/2006 | CN1731988A Sustained release pharmaceutical composition |
| 02/08/2006 | CN1731979A Allergen dosage form |
| 02/08/2006 | CN1730650A Foot-and-mouth disease virus resistant recombinant live bacteria and its preparation method |
| 02/08/2006 | CN1730493A Mouse single-chain antibody of anti- nasopharyngeal carcinoma and its DNA sequence |
| 02/08/2006 | CN1730101A O-type foot-and-mouth disease virus poly-gene duplication defect type adenovirus active carrier vaccine and process for preparing the same |
| 02/08/2006 | CN1729996A Process for preparing high-immune serum for main epidemic disease of dog and formulation thereof |
| 02/08/2006 | CN1240836C Transforming growth factor alpha HI |
| 02/08/2006 | CN1240721C Conjugate of lidamycin, monoclonal antibody and its Fab'segment and its application in targeting treatment of colon cancer and other tumors |
| 02/08/2006 | CN1240714C Chirality peptide antigen and vaccine composition based on core sequence of mucin 1 |
| 02/07/2006 | US6995299 Model system for Hepatitis C virus infection in humans, comprising non-human animal rendered immunologically tolerant to human hepatocytes and subsequently transplanted with human hepatocytes and infected with Hepatitis C |
| 02/07/2006 | US6995255 Cellular delivery agent |
| 02/07/2006 | US6995254 Given sequences; vectors; host cells; use as a drug target to screen for novel antibiotics as FAB I is involved in bacterial fatty acid biosynthesis |
| 02/07/2006 | US6995252 A polynucleotide encoding a perinuclear thecaprotein (PT 32) which binds to tyrosine kinase c-Yes to induce oocyte activation; enhancing fertility, treating or diagnosing diminished fertility and/or abnormal spermiogenesis; contraception; screeing |
| 02/07/2006 | US6995244 A mutant binding to prolactin receptor through site 1, does not bind through site 2 nor has diminished binding through site 2, and exhibits <1% of unmodified agonist activity; anticarcinogenic, -tumor and metastatis agents; breast/prostate cancer |
| 02/07/2006 | US6995241 Acute Neuronal Induced Calcium-Binding Protein (ANIC-BP-1B) polypeptides and polynucleotides; diagnostic assays; neuroprotectants; agonists; antagonists; stroke , Parkinson's disease, Alzheimer disease, multiple sclerosis and spinal cord injuries |
| 02/07/2006 | US6995240 Treatment of inflammatory disease |
| 02/07/2006 | US6995237 Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions |
| 02/07/2006 | US6995164 Methods of treating tumors |
| 02/07/2006 | US6994994 Of the tumor necrosis factor receptor family; given amino acid sequence; use treating diseases and disorders ameliorated or cured by decreasing the levels of ligands of the original CD40R such as autoimmune diseases |